Following landmark demonstration, Madrona Ventures leads $6 million expansion of Series A Round BELLEVUE, Wash, Dec. 14, 2023 /PRNewswire/ — Today, Lassen Peak announces the world’s first demonstration of handheld concealed weapon detection using Terahertz frequency imaging radar. The Lassen Peak team demonstrated successful detection of concealed weapons using a functional Proof of Concept (PoC)… Continue reading Lassen Peak Demonstrates World’s First Handheld Concealed Weapon Detection at IACP
Category: Newswire
Driven Brands announces appointment of Damien Harmon to Board of Directors
Company adds new independent director CHARLOTTE, N.C., Dec. 19, 2023 /PRNewswire/ — Driven Brands Holdings (NASDAQ: DRVN), today announced the election of Damien Harmon to its Board of Directors, effective January 1, 2024. Harmon will also serve as a member of the Compensation Committee. “We’re thrilled to have Damien join our Board,” said Jonathan Fitzpatrick,… Continue reading Driven Brands announces appointment of Damien Harmon to Board of Directors
Alora Pharmaceuticals, LLC announces the availability of Once-Daily Relexxii® for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)
ALPHARETTA, Ga., Dec. 19, 2023 /PRNewswire/ — Alora Pharmaceuticals, LLC, the parent company of Vertical Pharmaceuticals, LLC, announced today the commercial availability of Relexxii® (methylphenidate hydrochloride extended-release tablets). Relexxii is a once-daily central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults (up to the age of 65… Continue reading Alora Pharmaceuticals, LLC announces the availability of Once-Daily Relexxii® for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Dosing of first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody, will trigger $10 million milestone payment from AstraZeneca HOLON, Israel, Dec. 19, 2023 /PRNewswire/ — Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it will be eligible to receive a milestone payment… Continue reading Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Lufthansa Group to Buy up to 100 737 MAX Jets in First Boeing Single-Aisle Order in Nearly 30 Years
SEATTLE, Dec. 19, 2023 /PRNewswire/ — Boeing [NYSE: BA] and the Lufthansa Group today announced a landmark 737 MAX order for up to 100 jets that will see Europe’s largest airline group restore the Boeing 737 family into its fleet. The commitment includes a firm order for 40 737-8 airplanes with 60 options. “It is… Continue reading Lufthansa Group to Buy up to 100 737 MAX Jets in First Boeing Single-Aisle Order in Nearly 30 Years
MESCIUS inc. Releases Wijmo 2023 v2
PITTSBURGH, Dec. 19, 2023 /PRNewswire/ — MESCIUS inc., a global provider of award-winning enterprise software development tools, is pleased to announce the Wijmo 2023 v2 release. The final release of 2023 includes significant accessibility enhancements, FlexGrid improvements, and more. The main focus of this release has been quality, as it consists of many essential fixes… Continue reading MESCIUS inc. Releases Wijmo 2023 v2
Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology
Conference call today, December 19, 2023, 8:30 AM ET to discuss the license agreement HOLON, Israel, Dec. 19, 2023 /PRNewswire/ — Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will host a conference call at 8:30 AM ET today, to discuss the… Continue reading Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology
MDsave Announces Partnership with Fountain Point Surgery Center Increasing Access to Affordable Care for Self-Paying Patients
NASHVILLE, Tenn., Dec. 19, 2023 /PRNewswire/ — MDsave, the nation’s leading healthcare services platform connecting providers, employers, and patients to transparent and transactable healthcare, announces today its partnership with Fountain Point Surgery Center. Fountain Point Surgery Center is a multi-specialty ambulatory surgical facility in Norfolk, Nebraska that provides the highest quality care to patients in… Continue reading MDsave Announces Partnership with Fountain Point Surgery Center Increasing Access to Affordable Care for Self-Paying Patients
Recipharm Harmonizes its Global Quality Operations with Veeva Vault Quality
Leading CDMO adopts Veeva Vault QMS, Vault QualityDocs, and Vault Training to standardize quality processes and manage GxP content across its organization BARCELONA, Spain, Dec. 19, 2023 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that Recipharm, a global contract development and manufacturing organization (CDMO), will use Veeva Vault QMS, Veeva Vault QualityDocs, and Veeva… Continue reading Recipharm Harmonizes its Global Quality Operations with Veeva Vault Quality
Recipharm Harmonizes its Global Quality Operations with Veeva Vault Quality
Leading CDMO adopts Veeva Vault QMS, Vault QualityDocs, and Vault Training to standardize quality processes and manage GxP content across its organization PLEASANTON, Calif., Dec. 19, 2023 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that Recipharm, a global contract development and manufacturing organization (CDMO), will use Veeva Vault QMS, Veeva Vault QualityDocs, and Veeva… Continue reading Recipharm Harmonizes its Global Quality Operations with Veeva Vault Quality